Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Aprea Presents Preclinical Data at AACR

Published: Tuesday, April 08, 2014
Last Updated: Tuesday, April 08, 2014
Bookmark and Share
Data reveals that APR-246 resensitizes ovarian cancer cells to platinum compounds and doxorubicin.

Aprea AB has presented preclinical data at the American Association for Cancer Research (AACR) meeting in San Diego, USA. The data reveals that Aprea's candidate drug APR-246, a compound that reactivates mutant p53, is able to resensitize ovarian cancer cells to platinum compounds and doxorubicin.

A Phase Ib/II study with APR-246 in relapsed platinum sensitive ovarian cancer is currently open for recruitment. Aprea is part of the Karolinska Development portfolio.

Platinum-based drugs are since decades used as first-line treatment for many solid tumors. Patients with ovarian cancer often respond well to platinum compounds, but many of these patients develop resistance to platinum and die of chemotherapy refractory disease.

The mechanisms underlying resistance are multifactorial, but two of the main causes are mutations in the tumor suppressor protein p53 and elevated intracellular glutathione levels.

The preclinical data presented shows that APR-246 not only reactivates mutant p53, but also decreases intracellular glutathione levels in a dose-dependent manner. This unique mechanism of action, targeting both mutant p53 and glutathione, is likely to account for the strong synergistic effects of APR-246 and platinum drugs as well as resensitization of ovarian cancer cells, which were observed in the study.

“The results provide a strong rationale for the clinical trial in intermediate platinum resistant ovarian cancer and suggest that treatment with APR-246 in combination with platinum-based chemotherapy could have a broad applicability in the treatment of drug resistant p53 mutant human tumors”, comments Mikael von Euler, CMO of Aprea.

The title of Aprea’s poster presentation at AACR was “APR-246, a clinical-stage mutant p53-reactivating compound, resensitizes ovarian cancer cells to platinum compounds and doxorubicin”. The full abstract (Abstract # 1801), is available on www.aacr.org.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aprea Presents Preliminary Clinical Phase Ib/II Results in Ovarian Cancer at AACR
Company presents results with APR-246 - a novel candidate drug that restores mutant p53 protein into its wild-type function.
Tuesday, April 21, 2015
Dosing Initiated in Phase I/II Clinical Trial of APR-246 in Ovarian Cancer
Promising data from trial has been presented in Journal of Clinical Oncology.
Thursday, April 17, 2014
Scientific News
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Genes That Increase Children's Risk Of Blood Infection Identified
A team led by Oxford University has identified genes that make certain children more susceptible to invasive bacterial infections by performing a large genome-wide association study in African children.
Poverty Marks a Gene, Predicting Depression
New study of high-risk teens reveals a biological pathway for depression.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!